Emerging PEGylated drugs
- 20 May 2009
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Drugs
- Vol. 14 (2), 363-380
- https://doi.org/10.1517/14728210902907847
Abstract
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic molecules. Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small organic molecules. Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities. This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.Keywords
This publication has 83 references indexed in Scilit:
- In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheresInternational Journal of Pharmaceutics, 2007
- Pharmacodynamics of peginterferon alfa‐2a and peginterferon alfa‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled studyAlimentary Pharmacology & Therapeutics, 2007
- Pegylated arginine deiminase: a novel anticancer enzyme agentExpert Opinion on Investigational Drugs, 2006
- Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A reviewClinical Therapeutics, 2006
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic ProteinsClinical Pharmacokinetics, 2005
- Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis CPharmacoEconomics, 2004
- Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) StudyJournal of Clinical Oncology, 2003
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Peptide and protein PEGylation: a review of problems and solutionsBiomaterials, 2001